surpass cvot tirzepatide results Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Post hoc analysis of SURPASS-CVOT

The peripheral compartment adds another 3.98 liters

Kidney function, liver function, and gastrointestinal tolerance must be assessed before progressing to higher doses

Zhang Q, Delessa CT, Augustin R, et al

Conclusion The DREAMS-3 trial demonstrated that, in patients with type 2 diabetes with obesity, Mazdutide achieved superior outcomes to Semaglutide in both glycemic control and weight reduction

These positive changes contribute to a reduced risk of developing or worsening obesity-related comorbidities, enhancing overall health and longevity

When sulphur-containing foods such as eggs, meat, dairy products, and certain vegetables undergo digestion, gut bacteria can produce hydrogen sulphide gas as a metabolic by-product